References
- LawrenceRCFelsonDTHelmickCGEstimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part IIArthritis Rheum2008581263518163497
- SakalauskieneGJauniskieneDOsteoarthritis: etiology, epidemiology, impact on the individual and society and the main principles of managementMedicina (Kaunas)2010461179079721467838
- KopecJARahmanMMBerthelotJMDescriptive epidemiology of osteoarthritis in British Columbia, CanadaJ Rheumatol200734238639317183616
- Martel-PelletierJPelletierJPIs osteoarthritis a disease involving only cartilage or other articular tissues?Eklem Hastalik Cerrahisi201021121420302555
- BreedveldFCOsteoarthritis – the impact of a serious diseaseRheumatology (Oxford)200443Suppl 1i4i814752169
- AxfordJHeronCRossFVictorCRManagement of knee osteoarthritis in primary care: pain and depression are the major obstaclesJ Psychosom Res200864546146718440398
- ZhangWMoskowitzRWNukiGOARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesOsteoarthritis Cartilage200816213716218279766
- AvouacJGossecLDougadosMEfficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trialsOsteoarthritis Cartilage200715895796517398122
- CaldwellJRRapoportRJDavisJCEfficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trialJ Pain Symptom Manage200223427829111997197
- MatsumotoAKBabulNAhdiehHOxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trialPain Med20056535736616266356
- NicholsonBBenefits of extended-release opioid analgesic formulations in the treatment of chronic painPain Pract200991718119019047
- WielandHAMichaelisMKirschbaumBJRudolphiKAOsteoarthritis – an untreatable disease?Nat Rev Drug Discov20054433134415803196
- Arendt-NielsenLNieHLaursenMBSensitization in patients with painful knee osteoarthritisPain2010149357358120418016
- WoolfCJCentral sensitization: implications for the diagnosis and treatment of painPain2011152Suppl 3S2S1520961685
- Management of chronic pain syndromes: issues and interventionsPain Med20056Suppl 1S1S2016392534
- CuratoloMArendt-NielsenLPetersen-FelixSCentral hypersensitivity in chronic pain: mechanisms and clinical implicationsPhys Med Rehabil Clin N Am200617228730216616268
- SommerCIs serotonin hyperalgesic or analgesic?Curr Pain Headache Rep200610210110616539862
- SuzukiRRyghLJDickensonAHBad news from the brain: descending 5-HT pathways that control spinal pain processingTrends Pharmacol Sci2004251261361715530638
- BenyaminRTrescotAMDattaSOpioid complications and side effectsPain Physician200811Suppl 2S105S12018443635
- FurlanADSandovalJAMailis-GagnonATunksEOpioids for chronic noncancer pain: a meta-analysis of effectiveness and side effectsCMAJ2006174111589159416717269
- PorrecaFOssipovMHNausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management optionsPain Med200910465466219302436
- TzschentkeTMChristophTKögelB(−)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel μ–opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic propertiesJ Pharmacol Exp Ther2007323126527617656655
- TzschentkeTMDe VryJTerlindenRTapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitorDrugs Future2006311210531061
- AfilaloMEtropolskiMSKuperwasserBEfficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III studyClin Drug Investig2010308489505
- LangeBKuperwasserBOkamotoAEfficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back painAdv Ther201027638139920556560
- WildJEGrondSKuperwasserBLong-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis painPain Pract201010541642720602712
- DworkinRHTurkDCFarrarJTCore outcome measures for chronic pain clinical trials: IMMPACT recommendationsPain20051131–291915621359
- FarrarJTYoungJPJrLaMoreauxLWerthJLPooleRMClinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scalePain200194214915811690728
- SchneiderLSOlinJTDoodyRSValidity and reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer’s Disease Cooperative StudyAlzheimer Dis Assoc Disord199711Suppl 2S22S329236949
- BellamyNBuchananWWGoldsmithCHCampbellJStittLWValidation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or kneeJ Rheumatol19881512183318403068365
- SelaiCETrimbleMRPriceMJRemakEEvaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugsCurr Med Res Opin200521573373915969872
- WareJEJrSherbourneCDThe MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selectionMed Care19923064734831593914
- BjellandIDahlAAHaugTTNeckelmannDThe validity of the Hospital Anxiety and Depression Scale. An updated literature reviewJ Psychosom Res2002522697711832252
- BellamyNWOMAC Osteoarthritis Index: User Guide IVQueensland, AustraliaWOMAC2000
- SnaithRPThe Hospital Anxiety And Depression ScaleHealth Qual Life Outcomes200312912914662
- ZigmondASSnaithRPThe hospital anxiety and depression scaleActa Psychiatr Scand19836763613706880820
- GwilymSEKeltnerJRWarnabyCEPsychophysical and functional imaging evidence supporting the presence of central sensitization in a cohort of osteoarthritis patientsArthritis Rheum20096191226123419714588
- HochmanJRFrenchMRBerminghamSLHawkerGAThe nerve of osteoarthritis painArthritis Care Res (Hoboken)20106271019102320589688
- NikolajsenLBrandsborgBLuchtUJensenTSKehletHChronic pain following total hip arthroplasty: a nationwide questionnaire studyActa Anaesthesiol Scand200650449550016548863
- PuolakkaPARorariusMGRoviolaMPuolakkaTJNordhausenKLindgrenLPersistent pain following knee arthroplastyEur J Anaesthesiol201027545546020299989
- WyldeVHewlettSLearmonthIDDieppePPersistent pain after joint replacement: prevalence, sensory qualities, and postoperative determinantsPain2011152356657221239114
- LundbladHKreicbergsAJanssonKAPrediction of persistent pain after total knee replacement for osteoarthritisJ Bone Joint Surg Br200890216617118256082
- LoeserRFMolecular mechanisms of cartilage destruction in osteoarthritisJ Musculoskelet Neuronal Interact20088430330619147949
- WaltersSJBrazierJEComparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6DQual Life Res20051461523153216110932
- SamsaGEdelmanDRothmanMLWilliamsGRLipscombJMatcharDDetermining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark IIPharmacoeconomics199915214115510351188
- GregorianRSJrGasikAKwongWJVoellerSKavanaghSImportance of side effects in opioid treatment: a trade-off analysis with patients and physiciansJ Pain201011111095110820452835
- MarkensonJACroftJZhangPGRichardsPTreatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trialClin J Pain200521652453516215338